Non-Surgical Interventions for the Prevention of Clinically Relevant Postoperative Pancreatic Fistula—A Narrative Review

Non-Surgical Interventions for the Prevention of Clinically Relevant Postoperative Pancreatic Fistula—A Narrative Review

Clinically relevant postoperative pancreatic fistula (CR-POPF) is the leading cause of morbidity and mortality after pancreatic surgery. Post-pancreatectomy acute pancreatitis (PPAP) has been increasingly understood as a precursor and exacerbator of CR-POPF. No longer believed to be the consequence...

Full description

Bibliographic Details
Main Authors:	Nadya Rykina-Tameeva, Jaswinder S. Samra, Sumit Sahni, Anubhav Mittal
Format:	Article
Language:	English
Published:	MDPI AG 2023-12-01
Series:	Cancers
Subjects:	clinically relevant postoperative pancreatic fistula neoadjuvant therapy somatostatin somatostatin analogues antibiotics analgesia
Online Access:	https://www.mdpi.com/2072-6694/15/24/5865

Similar Items

Role of Somatostatin Signalling in Neuroendocrine Tumours
by: Olesja Rogoza, et al.
Published: (2022-01-01)

Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course
by: Robert Pichler, et al.
Published: (2021-06-01)

Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
by: Vera G. Megdanova-Chipeva, et al.
Published: (2020-07-01)

Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin
by: Prudencio Sáez-Martínez, et al.
Published: (2022-10-01)

Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist
by: Pooja Dasgupta, et al.
Published: (2021-10-01)

The Crystal Structure Elucidation of a Tetrapeptide Analog of Somatostatin DOTA-Phe-D-Trp-Lys-Thr-OMe
by: Sabina Diusenova, et al.
Published: (2021-12-01)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
by: Maria Isabel del Olmo-Garcia, et al.
Published: (2021-12-01)

Postoperative Treatment in a Patient After Hemithyroidectomy: the Therapeutic Challenges of a Hidden Thyrotropinoma
by: Sabine Vermeersch, et al.
Published: (2015-07-01)

Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies
by: Lingaku Lee, et al.
Published: (2022-02-01)

Role of Receptor Profiling for Personalized Therapy in a Patient with a Growth Hormone-Secreting Macroadenoma Resistant to First-Generation Somatostatin Analogues
by: Krystallenia I. Alexandraki, et al.
Published: (2019-11-01)

Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review
by: Anna La Salvia, et al.
Published: (2021-10-01)

Long action somatostatin analogues in patients with TSH-secreted pituitary adenomas: treatment experience
by: L. K. Dzeranova, et al.
Published: (2022-02-01)

The Clinico-epidemiologic Characteristics of Iraqi Patients with Neuroendocrine Tumors and Their Response to Long Acting Octreotide
by: Marwah K. Abdulfattah, et al.
Published: (2016-01-01)

Chromogranin A: As A Tumor Marker for Neuroendocrine Tumors Diagnosis, Follow-up & Its Correlation with Response to Somatostatin Analogues
by: Manwar A. Mohammed AL-Naqqash
Published: (2016-01-01)

Small Bowel Neuroendocrine Tumors—10-Year Experience of the Ottawa Hospital (TOH)
by: Abdulhameed Alfagih, et al.
Published: (2023-08-01)

The Role of Somatostatin Analogues in the Control of Diarrhea and Flushing as Markers of Carcinoid Syndrome: A Systematic Review and Meta-Analysis
by: Krystallenia I. Alexandraki, et al.
Published: (2023-02-01)

CURRENT VIEWS ON THE TREATMENT OF ACROMEGALY WITH SOMATOSTATIN ANALOGUES
by: I. A. Ilovaiskaya
Published: (2017-12-01)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
by: Sang Ouk Chin, et al.
Published: (2019-03-01)

Somatostatin and Somatostatin Receptors in Tumour Biology
by: Ujendra Kumar
Published: (2023-12-01)

Somatostatin and Somatostatin-Containing Interneurons—From Plasticity to Pathology
by: Monika Liguz-Lecznar, et al.
Published: (2022-02-01)

Molecular and Clinical Implications of Somatostatin Receptor Profile and Somatostatin Analogues Treatment in Oral Cavity Squamous Cell Carcinoma
by: Alba Sanjuan-Sanjuan, et al.
Published: (2021-09-01)

Meningiomas and Somatostatin Analogs: A Systematic Scoping Review on Current Insights and Future Perspectives
by: Sofie Eline Tollefsen, et al.
Published: (2023-03-01)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE
by: Ralf S. Eschbach, et al.
Published: (2023-01-01)

Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review
by: Shista Priyadarshini, et al.
Published: (2022-07-01)

Role of Somatostatin in the Regulation of Central and Peripheral Factors of Satiety and Obesity
by: Ujendra Kumar, et al.
Published: (2020-04-01)

Postoperative Hypophosphatemia as a Prognostic Factor for Postoperative Pancreatic Fistula: A Systematic Review
by: Ieva Grikyte, et al.
Published: (2023-01-01)

The Dose of Somatostatin Analogues during Pre-Surgical Treatment Is a Key Factor to Achieve Surgical Remission in Acromegaly
by: Marta Araujo-Castro, et al.
Published: (2021-08-01)

Modern methods of medical treatment of acromegaly
by: V. S. Pronin, et al.
Published: (2020-01-01)

Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment Alone
by: Yannis Mesli, et al.
Published: (2021-11-01)

Targeted treatment with somatostatin analogues: widening horizons of clinical practice
by: Vyacheslav S. Pronin, et al.
Published: (2022-10-01)

Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin
by: Charles eBrunicardi, et al.
Published: (2014-06-01)

ALTERNATIVE FISTULA RISK SCORE AND FIRST POSTOPERATIVE DAY DRAIN FLUID AMYLASE AS PREDICTORS OF PANCREATIC FISTULA AFTER PANCREATICODUODENECTOMY
by: Karina Scalabrin Longo, et al.
Published: (2023-05-01)

Responses to Medical Treatment in 192 Patients with Pancreatic Neuroendocrine Neoplasms Referred to the Copenhagen Neuroendocrine Tumour Centre in 2000–2020
by: Sofie Skovlund Petersen, et al.
Published: (2024-03-01)

Preoperative detection of functional somatostatin receptors in a patient with an insulinoma
by: Kohei Oguni, et al.
Published: (2023-08-01)

Proposal of a Preoperative CT-Based Score to Predict the Risk of Clinically Relevant Pancreatic Fistula after Cephalic Pancreatoduodenectomy
by: Marius Lucian Savin, et al.
Published: (2021-06-01)

Percutaneous Endoscopic Necrosectomy (PEN) Combined with Percutaneous Catheter Drainage (PCD) and Irrigation for the Treatment of Clinically Relevant Pancreatic Fistula after Pancreatoduodenectomy
by: Jian Lin, et al.
Published: (2020-04-01)

New polyglycolic acid fabric for the prevention of postoperative pancreatic fistulas
by: Toshitaka Takagi, et al.
Published: (2018-01-01)

The Role of Somatostatin Treatment in the Management of Chylous Fistula after Neck Dissection
by: Nilda Süslü, et al.
Published: (2014-03-01)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
by: Rihards Saksis, et al.
Published: (2023-02-01)

Pancreatic duct occlusion with polychloroprene-based glue for the management of postoperative pancreatic fistula after pancreatoduodenectomy—an outdated approach?
by: Sheraz Yaqub, et al.
Published: (2024-04-01)